MARKET

MESO

MESO

Mesoblast
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.25
-0.23
-2.43%
Pre Market: 9.30 +0.05 +0.54% 07:23 01/25 EST
OPEN
9.35
PREV CLOSE
9.48
HIGH
9.55
LOW
9.18
VOLUME
165
TURNOVER
--
52 WEEK HIGH
21.28
52 WEEK LOW
3.120
MARKET CAP
1.08B
P/E (TTM)
-10.3816
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Global Myocardial Infarction Treatment Market 2021 Global Trends, Demand, Segmentation and Opportunities Forecast To 2027
Jan 21, 2021 (Heraldkeepers) -- Global Myocardial Infarction Treatment Industry The myocardial infarction or heart attack is a life-threatening condition...
Heraldkeepers · 4d ago
Diabetic Nephropathy Market Size, Share, Growth, Trends and Upcoming Opportunities In 2020 – 2024
Jan 20, 2021 (AmericaNewsHour) -- Global Diabetic Nephropathy Market is estimated to reach $3,826 million by 2024; growing at a CAGR of 5.9% from 2016 to...
AmericaNewsHour · 5d ago
Epithelial Stem Cells (Escs) Market Share 2021: Qualitative Insights, Gross Margin, Competition Landscape, Growth Rate, Development Trends, Prominent Players and Opportunity Assessment till 2025
Jan 20, 2021 (The Expresswire) -- Global “Epithelial Stem Cells (Escs) Market” report is extensive significant analyses of the Epithelial Stem Cells (Escs)...
The Express Wire · 5d ago
DJ Mesoblast Cut to Hold From Buy by Jefferies
Dow Jones · 5d ago
Cell and Gene Therapy Tools and Reagents Market Key Players : ATHERSYS INC. AVROBIO BIO-RAD LABORATORIES BIO-TECHNE CELLGENIX
Jan 19, 2021 (Market Insight Reports) -- Global Cell and Gene Therapy Tools and Reagents Market 2020 | Clinical Analysis, Latest Innovations, Impacting...
Market Insight Reports · 6d ago
Is the Options Market Predicting a Spike in Mesoblast (MESO) Stock?
Zacks.com · 01/12 18:17
Company News for Jan 12, 2021
Companies in the news are: MESO, ODP, LLY, AZZ
Zacks · 01/12 14:32
Is the Options Market Predicting a Spike in Mesoblast (MESO) Stock?
Investors need to pay close attention to Mesoblast (MESO) stock based on the movements in the options market lately.
Zacks · 01/12 13:48
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MESO. Analyze the recent business situations of Mesoblast through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MESO stock price target is 14.96 with a high estimate of 23.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 73
Institutional Holdings: 3.42M
% Owned: 2.92%
Shares Outstanding: 117.16M
TypeInstitutionsShares
Increased
19
734.11K
New
25
470.96K
Decreased
8
781.60K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+0.80%
Key Executives
Non-Executive Chairman/Independent Director
Joseph Swedish
Chief Executive Officer/Executive Director
Silviu Itescu
Vice Chairman/Non-Executive Independent Director
William Burns
Chief Financial Officer
Joshua Muntner
Chief Operating Officer
Dagmar Rosa-Bjorkeson
Senior Vice President
Eric Strati
General Counsel
Peter Howard
Other
Fred Grossman
Other
John McMannis
Other
Paul Simmons
Other
Geraldine Storton
Secretary
Charlie Harrison
Secretary
Niva Sivakumar
Non-Executive Independent Director
Donal O'Dwyer
Non-Executive Independent Director
Eric Rose
Non-Executive Independent Director
Michael Spooner
Non-Executive Independent Director
Shawn Tomasello
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MESO
Mesoblast Limited is engaged in the development of regenerative medicine products. The Company’s regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high and unmet medical needs. The Company’s portfolio of Phase III product candidates comprises RYONCIL (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD), REVASCOR for advanced chronic heart failure (CHF) and MPC-06-ID for chronic low back pain due to degenerative disc disease. The Company's product candidate, MPC-150-IM, is in Phase III trials for the treatment of both advanced and end-stage CHF. The Company has conducted Phase II trial of MPC-300-IV in patients with biologic-refractory rheumatoid arthritis. The Company is developing MPC-25-Osteo for spinal fusion.
More

Webull offers kinds of Mesoblast limited (ADR) stock information, including NASDAQ:MESO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MESO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MESO stock methods without spending real money on the virtual paper trading platform.